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INTRODUCTION
Benign prostatic hyperplasia (BPH) is the most common uro-
logical disorder in older men, and its incidence is expected to 
rise with increasing life expectancy. Hypertension is also a 
common disease in older age adults. Studies suggest that age-
related increases in sympathetic noradrenergic activity may 
be a common pathophysiologic component in BPH and hyper-
tension.1-4 Even disregarding the possibility of a common pa-
thology, it is estimated that at least one in four men aged >60 
years could have concomitant BPH and hypertension.4,5
Selective α1-adrenoceptor (AR) antagonists are well known 
to be an effective, non-invasive treatment option for patients with 
BPH. Lower urinary tract symptoms (LUTS) can be improved by 
reduction of urethral pressure and prostatic smooth muscle tone 
by blocking the motor sympathetic adrenergic nerve supply to 
the prostrate. These agents are currently considered as first-line 
medical therapy for BPH patients,5-7 and numerous studies re-
garding their efficacy and tolerability have been reported.
Of these agents, naftopidil is an α1-AR antagonist that has high 
selectivity for the α1D subtype, showing 3- and 17-fold higher 
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affinity for this subtype than for α1A and α1B subtypes, respec-
tively.8,9 Although several clinical trials9-12 demonstrating the 
efficacy of this drug for BPH patients have been reported, there 
are few reports of the cardiovascular responses associated with 
this drug during BPH treatment. Here, we aimed to determine 
the efficacy and safety of naftopidil for BPH/LUTS patients, fo-
cusing on 1) changes in blood pressure (BP) and 2) patient sat-
isfaction and compliance.
MATERIALS AND METHODS
Study design 
This study was designed as a prospective, open-label study to 
determine the efficacy and safety of naftopidil (Flivas, Dong-A 
Pharmaceutical Co., Ltd., Seoul, Korea) at a single center (Yon-
sei University Health System, Severance Hospital, Seoul, Ko-
rea). The study protocol was approved by our Institutional Re-
view Board (IRB approval No. 4-2014-0503, Yonsei University 
Health System). Patients provided written consent to participate 
in the study after having received an explanation of the proto-
col, including awareness of possible side effects. 
Based on an assumption of a mean improvement in total in-
ternational prostate symptom score (IPSS) from baseline of 3.0, 
a standard deviation of 5.3, and the assumption that 20% of pa-
tients will not be valid for inclusion in the per-protocol popula-
tion, a sample size of at least 120 patients was required to ob-
tain a power of 90%, with type 1 error of 0.05 (for a two-sided 
test). Results are reported for the intention to treat (ITT) popu-
lation (all patients with a baseline BP and IPSS assessment and 
at least one valid post-baseline BP and IPSS assessment).
The enrolled patients suffered from LUTS and were consid-
ered fit for α1-AR antagonist treatment based on the decision 
of our physician. Patients who met the inclusion criteria were 
assigned into the normotensive (NT) group (defined as diastol-
ic BP <90 mm Hg in a sitting position) or hypertensive (HT) 
group (diastolic BP ≥90 mm Hg in a sitting position) and then 
randomly assigned by computer-generated random numbers 
into the naftopidil 50 mg group or 75 mg group for 12-week, once-
daily treatment. 
BP was measured according to previous published guide-
lines:13,14 1) patients were seated quietly for at least 5 minutes 
in a chair with their feet on the floor and arms at the level of the 
heart, 2) at least two measurements at 1–2 minute intervals were 
made, 3) we used a standard bladder (12–13×35 cm), a larger 
one for big arms, and 4) we deflated the cuff slowly (2 mm Hg/
sec). Patient visits occurred at study entry and after 4 weeks and 
12 weeks of treatment. Adverse events (AEs) were defined as 
symptoms that required discontinuation or change of the cur-
rent medication.
Study population 
The inclusion criteria included male ambulatory patients over 
50 years of age with LUTS (total IPSS greater than 8). Patients with 
the following conditions were excluded: allergic drug reaction 
to α1-AR antagonists, orthostatic hypotension, a history of pros-
tate-related surgery (open or endoscopic), suspicious prostate 
malignant condition on digital rectal examination and/or pros-
tate-specific antigen (PSA) >10 ng/mL, a history of recurrent 
urinary tract infection or bladder stones, renal impairment 
(creatinine clearance rate <30 mL/min), severe hepatic disor-
ders, the use of anticholinergic or cholinergic agents, the use 
of other α1-AR antagonists (tamsulosin, silodosin, alfuzosin, 
doxazocin, terazocin) within the previous 4 weeks, or the use 
of 5-reductase inhibitors or antiandrogens within the previous 
3 months. Patients who were currently receiving or were plan-
ning to take any α-receptor agonists or β-receptor antagonists 
were also excluded.
Study end-points and assessments 
The primary end-point of this study was to determine the safe-
ty and efficacy of naftopidil 50 and 75 mg treatment. This 
measure was assessed by analyzing changes from baseline in 
systolic/diastolic BP and total IPSS at 4 and 12 weeks. Second-
ary aims were to analyze 1) AEs; 2) improvement in IPSS obstruc-
tive/irritative subscores, IPSS quality of life (QoL) score, and 
maximum urinary flow rate (Qmax); and 3) benefit, satisfaction 
with treatment, and willingness to continue treatment (BSW) 
questionnaire with naftopidil 50 and 75 mg treatment at 4 and 12 
weeks. The safety population was all patients who were random-
ized and who received at least one dose of study medication.
Statistical analysis 
The two-sample t-test and Wilcoxon rank sum test were con-
ducted to analyze continuous variables, and the chi-square test 
was used to analyze categorical variables. Comparison of the 
efficacy variables was performed using an RM-ANOVA model 
with baseline values of the response variable as covariates for 
absolute change in IPSS from baseline. For efficacy evalua-
tions, the last observation carried forward was applied to ana-
lyze the ITT population. Statistical analysis was performed with 
Prism software (version 5.00; GraphPad Instat, San Diego, CA, 
USA). Results were considered significant at p<0.05.
RESULTS
Study design
A total of 120 patients were screened and 118 were enrolled in 
this study (Fig. 1). Of these, 90 NT patients and 28 HT patients 
were randomized to receive naftopidil 50 mg or naftopidil 75 
mg (group 1, NT 50 mg naftopidil; group 2, NT 75 mg naftopi-
dil; group 3, HT 50 mg naftopidil, group 4, HT 75 mg naftopi-
dil). In the NT group, 83 patients completed the study. The main 
reason for study discontinuation was AEs (6 patients, 6.6%), 
and one patient withdrew informed consent. In the HT group, 
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27 patients completed the study, and one discontinued because 
of loss during follow-up. 
Patient demographics and characteristics 
Baseline demographics and characteristics for all patients in 
the ITT population are shown in Table 1. There were no significant 
Fig. 1. Patient disposition. A total of 120 patients were screened and 118 were enrolled in this study. Ninety normotensive (NT) patients and 28 hyper-
tensive (HT) patients were randomly assigned into the naftopidil 50 mg or naftopidil 75 mg group for 12-week, once-daily treatment. In the NT group, 
83 patients completed the study. The main reason for study discontinuation was AEs (6 patients, 6.6%). In the HT group, 27 patients completed the 
study, and one discontinued because of loss during follow-up. AE, adverse event.
Randomized into 2 groups based on
computer-generated random number table
Randomized into 2 groups based on
computer-generated random number table
Due to AE (n=4)
Consent withdrawn (n=1)
Due to AE (n=2) Lost to follow-up (n=1)
Completed
(n=34)
Completed
(n=49)
Completed
(n=12)
Completed
(n=15)
Withdrawn
(n=1)
Withdrawn
(n=2)
Withdrawn
(n=5)
Naftopidil 50 mg
(n=39)
Naftopidil 50 mg
(n=12)
HT (n=28)NT (n=90)
Patients screened 
(n=120)
Screening failures
(n=2)
Naftopidil 75 mg
(n=51)
Naftopidil 75 mg
(n=16)
Table 1. Patient Demographics and Baseline Characteristics
Normotension Hypertension
p valueGroup 1 
(naftopidil 50 mg)
Group 2 
(naftopidil 75 mg)
Group 3 
(naftopidil 50 mg)
Group 4 
(naftopidil 75 mg)
No. of patients 39 51 12 16 -
Mean (SD)
Age, yr 65.5 (7.0)0 67.2 (6.5)0 62.2 (4.3)0 64.1 (7.4)0 0.151
Height, cm 168.4 (4.2) 166.9 (7.2) 168.4 (4.2) 170.7 (6.3) 0.382
Weight, kg 65.6 (7.0)0 67.8 (11)0. 69.2 (6.9)0 70.5 (10.2) 0.548
SBP, mm Hg 123.1 (10.1) 124.9 (12.4) 144.4 (21.0) 145.3 (6.6) <0.001
DBP, mmHg 78.1 (6.5)0 77.1 (9.7)0 4.0 (3.0)0 93.5 (2.8)0 <0.001
Prostate volume, mL 30.4 (9.9) 31.9 (8.4) 7.5 (7.3) 35.0 (10.6) 0.394 
PSA, ng/mL 1.5 (1.1)0 1.9 (2.2)0 1.3 (1.3)0 1.9 (1.7)0 0.703
IPSS (baseline)
Total 18.8 (5.2)0 19.8 (6.5)0 17.4 (5.6)0 17.5 (3.1)0 0.595
Obstructive subscore 13.3 (4.3) 13.5 (5.1) 12.1 (4.2) 12.2 (3.9) 0.822
Irritative subscore 5.3 (2.2)0 6.3 (2.7)0 5.2 (3.0)0 5.3 (1.9)0 0.425 
QoL score 4.1 (0.7) 4.5 (0.7) 4.0 (0.8) 4.2 (0.8) 0.169
Qmax, mL/sec 11.7 (2.8)0 10.8 (2.7)0 11.6 (3.3)0 9.6 (3.0)0 0.260
PVR, mL 26.1 (27.5) 30.7 (38.3) 20.0 (19.7) 44.2 (55.6) 0.532
Race (%)
Asian 100 100 100 100 -
SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; PSA, prostate specific antigen; IPSS, international prostate symptom score; 
QoL, quality of life; Qmax, maximum urinary flow rate; PVR, post-void residual urine volume.
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differences between the four treatment groups in regards to age, 
height, weight, prostate volume, level of PSA, total IPSS scores, 
IPSS obstructive or irritative subscore, QoL due to urinary symp-
toms, Qmax, or post-void residual urine volume. Systolic and 
diastolic BP were significantly different between groups 1 and 
2 and groups 3 and 4 (p<0.001).
Influence on BP 
Naftopidil treatment decreased the mean systolic BP by 18.7 
mm Hg for group 3 (p<0.001) and by 18.3 mm Hg for group 4 
(p<0.001) and the mean diastolic BP by 17.5 mm Hg for group 3 
(p<0.001) and by 14.7 mm Hg for group 4 (p=0.022) (Fig. 2). How-
ever, in the NT groups (both naftopidil 50 and 75 mg), naftopi-
dil caused no significant changes in BP from baseline values. 
After adjusting for age, significant changes in mean systolic and 
diastolic BPs from baseline values were found in group 3 and 
group 4 vs. group 1 and group 2 (Fig. 2). 
Efﬁcacy 
The efficacy of naftopidil 50 and 75 mg on LUTS is summa-
rized in Fig. 3. After 12 weeks of treatment, both groups showed 
significant improvements from baseline in total IPSS score 
(p<0.001). For both obstructive and irritative subscores, there 
were significant improvements from baseline to the final visit 
for both 50 and 75 mg doses (p<0.001 and p=0.028, respective-
ly). Also, IPSS QoL scores after treatment with both drug doses 
improved significantly at 12 weeks (p<0.001). Both groups 
showed significant improvement in Qmax from baseline at 12 
weeks (p=0.034 in naftopidil 50 mg group and p<0.001 in 75 mg 
group).
Safety 
AEs were reported in four of 51 patients (7.8%) receiving naftopi-
dil 50 mg and in two of 67 (2.9%) receiving naftopidil 75 mg 
(Table 2). No syncope was reported for either group. None of the 
patients reported retrograde ejaculation. Most AEs were mild 
or moderate in severity. 
Satisfaction and compliance
After completion of 12 weeks of treatment with naftopidil, sat-
isfaction and compliance with this drug were assessed using 
the BSW questionnaire (Table 3). In both the 50 and 75 mg group, 
>76.6% of all patients felt they benefited from the treatment 
and were satisfied therewith. Moreover, 95.7% of patients in 
the naftopidil 50 mg group and 86% in the 75 mg group agreed 
to continue their current medications. The reasons for discon-
tinuation were gastrointestinal trouble (n=2 in naftopidil 50 mg 
group and n=5 in 75 mg group) and dizziness (n=4 in naftopidil 
75 mg group).
 
DISCUSSION
Considering the high incidence of patients with concomitant 
BPH and hypertension, physicians are concerned about the 
influence of BP changes during α1-AR antagonist treatment in 
such cases. Many studies regarding BP change in patients with 
BPH/hypertension treated with α1-AR antagonist have been 
reported. In 1995, Kirby15 reported that 12 weeks of treatment 
with doxazosin resulted in significant reductions in BP in HT 
patients, whereas minimal reductions were found in placebo-
treated patients. Kaplan, et al.16 showed that doxazosin treatment 
did not cause a clinically significant BP change in NT patients. 
Chung and Hong5 reported that doxazosin gastrointestinal 
therapeutic system (GITS) treatment for 1 year resulted in a sig-
nificantly greater reduction in BP in HT patients, compared with 
NT patients. Lee, et al.3 compared the BP-lowering effect of α1-
AR antagonists in patients with or without concomitant antihy-
pertensive drug treatment and reported that doxazosin GITS 
treatment resulted in optimal management of BP within the 
normal range, especially in baseline HT BP patients, irrespective 
of concomitant antihypertensive medication. Fawzy, et al.4 dem-
onstrated that doxazosin is especially beneficial in the treat-
ment of concomitant BPH and hypertension. Considering that 
older men might already be taking multiple medications for oth-
er diseases, the use of a single drug for two diseases might be 
valuable. 
Fig. 2. Comparison of the mean changes in BP from baseline value ac-
cording to group. BP, blood pressure.
Normotensive group
Baseline BP
(mm Hg)
BP at 12 wks
(mm Hg)
76.878.1
123.0123.1
Group 1
-0.1
-1.3
Baseline BP
(mm Hg)
BP at 12 wks
(mm Hg)
74.677.1
124.0124.9
Group 2
-0.9
-2.5
Hypertensive group 
Baseline BP
(mm Hg)
BP at 12 wks
(mm Hg)
76.5
94.0
125.7
144.4
Group 3
-18.7
-17.5
Baseline BP
(mm Hg)
BP at 12 wks
(mm Hg)
78.8
93.5
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-18.3
-14.7
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The majority of these reports, however, concern doxazosin 
treatment. Because doxazosin is a non-uroselective α1-AR an-
tagonist, its influence on BP might be understandable. Howev-
er, there are few reports on BP change with naftopidil, an α1-AR 
antagonist that has a high affinity for the α1D subtype. In our 
institution, we experienced stabilization of BP during naftopi-
dil treatment for BPH/LUTS. From our experience, we think that 
this additional benefit of BPH medication results in increased 
satisfaction and compliance of the patients with this drug. There-
fore, we aimed to further investigate the influence of naftopidil, 
mainly focusing on the cardiovascular aspects (i.e., BP change), 
as well as its efficacy for LUTS and patient satisfaction/compli-
ance.
In terms of BP change with uroselective α1-AR antagonist in 
HT patients, a previous report3 showed that treatment with 
tamsulosin and alfuzosin resulted in only a slight reduction in 
systolic BP. However, in the present study, treatment with naf-
topidil 50 mg or 75 mg resulted in significant reductions in sys-
Fig. 3. Change in efficacy parameters from baseline to each visit in the ITT population. IPSS, international prostate symptom score; SD, standard devi-
ation; QoL, quality of life; Qmax, maximum urinary flow rate; ITT, intention to treat. 
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tolic and diastolic BP in baseline HT patients (Fig. 2). In NT pa-
tients, systolic and diastolic BP were optimally managed with 
naftopidil.
The pharmacological mechanism of the BP-lowering effect 
associated with naftopidil could be related to calcium-chan-
nel-blocking activity. In 1991, Himmel, et al.17 reported that naf-
topidil could act as a weak ligand for L-type calcium channels, 
leading to ca2+ antagonistic effects. Similarly, several reports18,19 
demonstrated that naftopidil has both α-AR and calcium-block-
ing activity. We think further studies are needed to address this. 
In the present study, results from the BSW questionnaire sug-
gested that treatment with naftopidil also shows increased sat-
isfaction and compliance with this drug among patients. In both 
the 50 and 75 mg groups, the majority of patients felt benefit 
with satisfaction and agreed to continue this drug (Table 3).
Analysis of the BP-lowering effect of naftopidil with or with-
out concomitant antihypertensive medication revealed signifi-
cant reductions in systolic and diastolic BP in baseline HT pa-
tients, irrespective of concomitant antihypertensive medication 
(data not shown). These results are consistent with the previous 
report by Lee, et al.3 Regarding efficacy, the overall efficacy of 
BPH treatment with naftopidil for 12 weeks in the present study 
was similar to the results of a previous study.9 When comparing 
naftopidil 50 mg vs. 75 mg groups, overall efficacy parameters 
were superior with the higher dose (75 mg), although the dif-
ferences were not statistically significant (Fig. 3). In addition, 
several studies10,20-23 on naftopidil treatment reported improve-
ment of irritative symptoms with this drug. Nishino, et al.10 re-
ported that naftopidil was better than tamsulosin for nocturia. 
Other series24-26 suggested that upregulation of α1D-AR in the 
bladder contributes to the storage symptoms observed in blad-
der outlet obstruction and that targeting the α1D-AR with naf-
topidil may provide a new therapeutic approach for controlling 
storage symptoms in patients with BPH. However, in our study, 
we noted little difference in improvement in storage symptoms, 
compared with other α1-AR antagonists.
There are several limitation in our study. First, the study in-
cluded a relatively small number of patients and a short peri-
od of follow-up. Second, we measured BP only with the patient 
in the seated position. We acknowledge the methodological 
flaw of not measuring BP in a supine position, in addition to the 
sitting position, to rule out any orthostatic hypotension that 
might be present. Finally, we were unable to determine why the 
naftopidil treatment lowered BP in HT patients, compared with 
NT patients, and future studies to elucidate the underlying 
mechanism will be needed. However, we think that our results 
provide adequate preliminary data to support the additional 
benefit (optimal management of BP within the normal range) 
of naftopidil treatment in BPH/LUTS patients.
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